Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).

Creech CB, Frenck RW, Fiquet A, Feldman R, Kankam MK, Pathirana S, Baber J, Radley D, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Open Forum Infect Dis. 2019 Dec 24;7(1):ofz532. doi: 10.1093/ofid/ofz532. eCollection 2020 Jan.

2.

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.

Schmoele-Thoma B, van Cleeff M, Greenberg RN, Gurtman A, Jones TR, Sundaraiyer V, Gruber WC, Scott DA.

Hum Vaccin Immunother. 2019;15(3):575-583. doi: 10.1080/21645515.2018.1538618. Epub 2019 Jan 16.

3.

The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.

Gurtman A, Begier E, Mohamed N, Baber J, Sabharwal C, Haupt RM, Edwards H, Cooper D, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2019;15(2):358-370. doi: 10.1080/21645515.2018.1523093. Epub 2018 Sep 27. Review.

4.

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults.

Inoue M, Yonemura T, Baber J, Shoji Y, Aizawa M, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Hum Vaccin Immunother. 2018;14(11):2682-2691. doi: 10.1080/21645515.2018.1496764. Epub 2018 Aug 17.

5.

Neutrophil killing of Staphylococcus aureus in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study.

Scully IL, McNeil LK, Pathirana S, Singer CL, Liu Y, Mullen S, Girgenti D, Gurtman A, Pride MW, Jansen KU, Huang PL, Anderson AS.

Diabetol Metab Syndr. 2017 Oct 3;9:76. doi: 10.1186/s13098-017-0276-3. eCollection 2017.

6.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.

Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Le Dren-Narayanin N, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A.

Vaccine. 2017 May 31;35(24):3256-3263. doi: 10.1016/j.vaccine.2017.04.049. Epub 2017 May 4.

7.

A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations.

Wysocki J, Center KJ, Brzostek J, Majda-Stanislawska E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kopińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A.

Vaccine. 2017 Apr 4;35(15):1926-1935. doi: 10.1016/j.vaccine.2017.02.035. Epub 2017 Mar 3.

8.

SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies.

Begier E, Seiden DJ, Patton M, Zito E, Severs J, Cooper D, Eiden J, Gruber WC, Jansen KU, Anderson AS, Gurtman A.

Vaccine. 2017 Feb 22;35(8):1132-1139. doi: 10.1016/j.vaccine.2017.01.024. Epub 2017 Jan 28.

PMID:
28143674
9.

Vaccine development to prevent Staphylococcus aureus surgical-site infections.

Mohamed N, Wang MY, Le Huec JC, Liljenqvist U, Scully IL, Baber J, Begier E, Jansen KU, Gurtman A, Anderson AS.

Br J Surg. 2017 Jan;104(2):e41-e54. doi: 10.1002/bjs.10454. Review.

PMID:
28121039
10.

Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants.

Martinón-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, Omeñaca F, Concheiro-Guisan A, Gimenez-Sanchez F, Szenborn L, Blázquez-Gamero D, Moreno-Galarraga L, Giardina PC, Sun G, Gruber WC, Scott DA, Gurtman A.

Pediatr Infect Dis J. 2017 Mar;36(3):326-332. doi: 10.1097/INF.0000000000001428.

PMID:
27902652
11.

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.

Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B; B1851020 Study Group.

Vaccine. 2016 Jun 24;34(30):3454-62. doi: 10.1016/j.vaccine.2016.04.093. Epub 2016 May 5.

PMID:
27155493
12.

Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention.

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, Jansen KU, Gurtman A, Anderson AS.

Expert Rev Vaccines. 2016 Nov;15(11):1373-1392. Epub 2016 May 9. Review.

PMID:
27118628
13.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.

Bryant KA, Frenck R, Gurtman A, Rubino J, Treanor J, Thompson A, Jones TR, Sundaraiyer V, Baxter LM, Gruber WC, Emini EA, Scott DA, Schmoele-Thoma B.

Vaccine. 2015 Oct 26;33(43):5854-5860. doi: 10.1016/j.vaccine.2015.08.080. Epub 2015 Sep 9.

PMID:
26362099
14.

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.

Togashi T, Okada K, Yamaji M, Thompson A, Gurtman A, Cutler M, Aizawa M, Gruber WC, Scott DA.

Pediatr Infect Dis J. 2015 Oct;34(10):1096-104. doi: 10.1097/INF.0000000000000819.

PMID:
26121200
15.

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.

Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

AIDS. 2015 Jul 17;29(11):1345-54. doi: 10.1097/QAD.0000000000000689.

16.

13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.

De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA.

Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23. Erratum in: Pediatr Blood Cancer. 2019 Feb;66(2):e27554.

PMID:
25810327
17.

13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.

Martinón-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawska E, Omeñaca F, Bernaola Iturbe E, Blazquez Gamero D, Concheiro-Guisán A, Gimenez-Sanchez F, Szenborn L, Giardina PC, Patterson S, Gruber WC, Scott DA, Gurtman A.

Pediatrics. 2015 Apr;135(4):e876-86. doi: 10.1542/peds.2014-2941. Epub 2015 Mar 16.

PMID:
25780077
18.

Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.

Kaplan SL, Center KJ, Barson WJ, Ling-Lin P, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Peters TR, Gurtman A, Scott DA, Trammel J, Gruber WC, Hulten KG, Mason EO.

Clin Infect Dis. 2015 May 1;60(9):1339-45. doi: 10.1093/cid/civ067. Epub 2015 Feb 3.

PMID:
25648240
19.

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.

Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.

PMID:
25395187
20.

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.

Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

J Infect Dis. 2015 Apr 1;211(7):1144-53. doi: 10.1093/infdis/jiu576. Epub 2014 Oct 29.

PMID:
25355940
21.
22.

Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.

Juergens C, Patterson S, Trammel J, Greenberg D, Givon-Lavi N, Cooper D, Gurtman A, Gruber WC, Scott DA, Dagan R.

Clin Vaccine Immunol. 2014 Sep;21(9):1277-81. doi: 10.1128/CVI.00172-14. Epub 2014 Jul 2.

23.

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2014 Apr 25;32(20):2364-74. doi: 10.1016/j.vaccine.2014.02.002. Epub 2014 Mar 5.

PMID:
24606865
24.

13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine.

Frenck R Jr, Thompson A, Senders S, Harris-Ford L, Sperling M, Patterson S, Devlin C, Jansen KU, Gruber WC, Emini EA, Scott DA, Gurtman A.

Pediatr Infect Dis J. 2014 Feb;33(2):183-9. doi: 10.1097/INF.0000000000000056.

PMID:
24136369
25.

Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

Diez-Domingo J, Gurtman A, Bernaola E, Gimenez-Sanchez F, Martinon-Torres F, Pineda-Solas V, Delgado A, Infante-Marquez P, Liang JZ, Giardina PC, Gruber WC, Emini EA, Scott DA.

Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.

PMID:
24004465
26.

Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.

Thompson A, Gurtman A, Patterson S, Juergens C, Laudat F, Emini EA, Gruber WC, Scott DA.

Vaccine. 2013 Oct 25;31(45):5289-95. doi: 10.1016/j.vaccine.2013.08.025. Epub 2013 Aug 20.

PMID:
23973321
27.

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinón-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA.

Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16.

PMID:
23965217
28.

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.

Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA.

Clin Infect Dis. 2013 Oct;57(7):952-62. doi: 10.1093/cid/cit428. Epub 2013 Jun 26.

PMID:
23804191
29.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3585-93. doi: 10.1016/j.vaccine.2013.05.010. Epub 2013 May 18.

30.

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.

Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3577-84. doi: 10.1016/j.vaccine.2013.04.085. Epub 2013 May 18.

31.

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.

Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

Vaccine. 2013 Aug 2;31(35):3594-602. doi: 10.1016/j.vaccine.2013.04.084. Epub 2013 May 18.

32.

13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.

Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group.

Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7.

PMID:
23306363
33.

Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.

Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA.

Pediatr Infect Dis J. 2013 Apr;32(4):383-8. doi: 10.1097/INF.0b013e318279e9a9.

PMID:
23104129
34.

Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.

Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, Schmöle-Thoma B.

Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. doi: 10.1128/CVI.00176-12. Epub 2012 Jun 27.

35.

13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.

Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Diez-Domingo J, Carmona A, Sidhu M, Sarkozy DA, Gruber WC, Emini EA, Scott DA; 3007 Study Group.

Pediatr Infect Dis J. 2012 Apr;31(4):392-9. doi: 10.1097/INF.0b013e31824b972b.

PMID:
22301472
36.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.

Frenck R Jr, Thompson A, Yeh SH, London A, Sidhu MS, Patterson S, Gruber WC, Emini EA, Scott DA, Gurtman A; 3011 Study Group.

Pediatr Infect Dis J. 2011 Dec;30(12):1086-91. doi: 10.1097/INF.0b013e3182372c6a.

PMID:
21983216
37.

Pheochromocytoma.

Edmonds S, Fein DM, Gurtman A.

Pediatr Rev. 2011 Jul;32(7):308-10. doi: 10.1542/pir.32-7-308. Review. No abstract available.

PMID:
21724908
38.

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine.

Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA; 501 and 006 study groups.

Vaccine. 2011 Aug 11;29(35):6042-8. doi: 10.1016/j.vaccine.2011.06.026. Epub 2011 Jun 23.

PMID:
21704105
39.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA; 004 Study Group.

Pediatrics. 2010 Sep;126(3):e493-505. doi: 10.1542/peds.2009-3027. Epub 2010 Aug 23.

PMID:
20732948
40.

Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals.

Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H.

Int J Tuberc Lung Dis. 2007 Nov;11(11):1190-5.

PMID:
17958980
41.

[Occupational exposure to hepatitis C virus].

Warley E, Desse J, Szyld E, Silva FN, Cetani S, Pereyra N, De Luca A, Gurtman A.

Medicina (B Aires). 2006;66(2):97-100. Spanish.

PMID:
16715755
42.

Tuberculosis transmission in police stations in a suburb of Buenos Aires, Argentina.

Ortiz MC, Viera GA, Gravina E, Gurtman A, Barrera LE, Ritacco V.

Int J Tuberc Lung Dis. 2005 Sep;9(9):1058-9. No abstract available.

PMID:
16158903
43.

JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy.

Koralnik IJ, Wüthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S.

Ann Neurol. 2005 Apr;57(4):576-80.

PMID:
15786466
44.

Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.

Cook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL, Wilson TE, Young MA, Hessol NA.

Am J Public Health. 2004 Jul;94(7):1133-40.

45.

Clinicians' knowledge, attitudes, and concerns regarding bioterrorism after a brief educational program.

Gershon RR, Qureshi KA, Sepkowitz KA, Gurtman AC, Galea S, Sherman MF.

J Occup Environ Med. 2004 Jan;46(1):77-83.

PMID:
14724481
46.

Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus.

Harlow SD, Cohen M, Ohmit SE, Schuman P, Cu-Uvin S, Lin X, Greenblatt R, Gurtman A, Khalsa A, Minkoff H, Young MA, Klein RS.

Am J Obstet Gynecol. 2003 Apr;188(4):881-6.

PMID:
12712080
47.

Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.

Cara A, Vargas J Jr, Keller M, Jones S, Mosoian A, Gurtman A, Cohen A, Parkas V, Wallach F, Chusid E, Gelman IH, Klotman ME.

Virology. 2002 Jan 5;292(1):1-5.

48.

Prevalence and predictors of skin disease in the Women's Interagency HIV Study (WIHS).

Mirmirani P, Hessol NA, Maurer TA, Berger TG, Nguyen P, Khalsa A, Gurtman A, Micci S, Young M, Holman S, Gange SJ, Greenblatt RM.

J Am Acad Dermatol. 2001 May;44(5):785-8.

PMID:
11312425
49.

Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: results from the Women's Interagency HIV Study.

Wilson TE, Massad LS, Riester KA, Barkan S, Richardson J, Young M, Gurtman A, Greenblatt R.

AIDS. 1999 Apr 1;13(5):591-8.

PMID:
10203384
50.

Management of antiretroviral therapy.

Gurtman A, Borrego F, Klotman ME.

Semin Nephrol. 1998 Jul;18(4):459-80. Review.

PMID:
9692357

Supplemental Content

Loading ...
Support Center